share_log

Avalo Therapeutics | 8-K: Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics | 8-K: Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics | 8-K:Avalo公佈2024年第一季度財務業績並提供業務最新情況
美股sec公告 ·  05/13 19:34
牛牛AI助理已提取核心訊息
Avalo Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2024, on May 13, 2024. The company announced a net loss of $121.3 million for the quarter, which was primarily attributed to the excess of warrant fair value over private placement proceeds. The initial fair value of the warrants at issuance was $194.9 million, exceeding the upfront gross proceeds of $115.6 million, resulting in a recognized loss. Avalo also disclosed a cash position of approximately $110 million as of March 31, 2024, and expects its cash runway to extend into 2027. The company is preparing to initiate a Phase 2 trial of AVTX-009 in hidradenitis suppurativa within the year and is also planning to develop the drug for at least one other chronic inflammatory indication. Additionally, Avalo is conducting strategic reviews of its quisovalimab and AVTX-008 programs. The company's stock is traded on the Nasdaq Capital Market under the symbol AVTX.
Avalo Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2024, on May 13, 2024. The company announced a net loss of $121.3 million for the quarter, which was primarily attributed to the excess of warrant fair value over private placement proceeds. The initial fair value of the warrants at issuance was $194.9 million, exceeding the upfront gross proceeds of $115.6 million, resulting in a recognized loss. Avalo also disclosed a cash position of approximately $110 million as of March 31, 2024, and expects its cash runway to extend into 2027. The company is preparing to initiate a Phase 2 trial of AVTX-009 in hidradenitis suppurativa within the year and is also planning to develop the drug for at least one other chronic inflammatory indication. Additionally, Avalo is conducting strategic reviews of its quisovalimab and AVTX-008 programs. The company's stock is traded on the Nasdaq Capital Market under the symbol AVTX.
Avalo Therapeutics, Inc.於2024年5月13日公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈本季度淨虧損1.213億美元,這主要歸因於認股權證公允價值超過私募收益。認股權證發行時的初始公允價值爲1.949億美元,超過了1.156億美元的前期總收益,導致了確認虧損。阿瓦洛還披露了截至2024年3月31日的現金狀況約爲1.1億美元,並預計其現金流將延續到2027年。該公司正準備在年內啓動 AVTX-009 治療化膿性汗腺炎的 2 期試驗,還計劃開發用於至少另一種慢性炎症適應症的藥物。此外,Avalo正在對其quisovalimab和 AVTX-008 項目進行戰略審查。該公司的股票在納斯達克資本市場上市,股票代碼爲AVTX。
Avalo Therapeutics, Inc.於2024年5月13日公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈本季度淨虧損1.213億美元,這主要歸因於認股權證公允價值超過私募收益。認股權證發行時的初始公允價值爲1.949億美元,超過了1.156億美元的前期總收益,導致了確認虧損。阿瓦洛還披露了截至2024年3月31日的現金狀況約爲1.1億美元,並預計其現金流將延續到2027年。該公司正準備在年內啓動 AVTX-009 治療化膿性汗腺炎的 2 期試驗,還計劃開發用於至少另一種慢性炎症適應症的藥物。此外,Avalo正在對其quisovalimab和 AVTX-008 項目進行戰略審查。該公司的股票在納斯達克資本市場上市,股票代碼爲AVTX。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。